The role of fluid biomarkers in the diagnosis of Alzheimer′s disease
10.3760/cma.j.cn113694-20220727-00580
- VernacularTitle:对体液生物标志物在阿尔茨海默病中诊断作用的思考
- Author:
Jianping JIA
1
;
Siqi XIE
Author Information
1. 首都医科大学宣武医院神经疾病高创中心 国家老年疾病临床医学研究中心，北京 100053
- Keywords:
Alzheimer disease;
Biomarkers;
Diagnosis;
Cerebrospinal fluid;
Blood
- From:
Chinese Journal of Neurology
2023;56(3):245-250
- CountryChina
- Language:Chinese
-
Abstract:
The rapid advancement of biomarker research in Alzheimer′s disease (AD) has improved the accuracy of AD diagnosis, facilitated its early diagnosis and intervention, and has significant implications for disease-modifying therapy research and evaluation. Since its introduction, the AT(N) system has grown in importance in both the clinical and research aspects of AD. However, the fluid biomarkers in the AT(N) system do not yet adequately reflect the complex pathophysiology of AD. Other fluid biomarkers associated with neuroinflammation, synaptic dysfunction, and vascular dysfunction should be a valuable addition to the AT(N). In recent years, the development and application of peripheral blood biomarkers have greatly enriched the fluid biomarker system for AD and are expected to greatly facilitate early screening and diagnosis of the disease. Here, a brief overview of current research on AT(N) and other pathogenesis-related fluid biomarkers is presented, and the article proposes that fluid biomarkers for AD should be studied from a variety of pathophysiological perspectives in order to improve their role in disease diagnosis. This article also discusses the role and limitations of fluid biomarkers in the diagnosis of AD, as well as the future development and application of fluid biomarkers in AD.
